SpringWorks Therapeutics: Multiple Opportunities, But No Sure-Fire Winners (SWTX)
Damir Khabirov/iStock via Getty Images Investment Overview – The Pros & Cons Of SpringWorks Back in November last year I shared a note on Seeking Alpha discussing SpringWorks Therapeutics (NASDAQ:SWTX), on the day the company received FDA approval for its oral gamma secretase inhibitor Ogsiveo (nirogacestat), for the treatment of adult patients with desmoid tumors….